The NHS in England has introduced a groundbreaking 'Trojan horse' therapy for the treatment of myeloma, significantly improving remission times for patients. It employs a more potent form of chemotherapy, belantamab mafodotin, that specifically targets cancerous plasma cells with minimal side effects. Paul Silvester, a patient who benefited from this therapy, experienced remarkable improvements in his health, allowing him to resume normal life activities. His case exemplifies the potential of this innovative treatment to enhance the quality of life for cancer patients.
Paul Silvester, an early recipient of the new Trojan horse therapy, shared that the treatment was 'life-changing' and allowed him 'to enjoy' life again.
Belantamab mafodotin, the new cancer therapy, is designed to target plasma cells while reducing side effects, marking a significant advancement in myeloma treatment.
Collection
[
|
...
]